Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets.Keytruda (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer.Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on Thursday.Subject to certain exceptions, each party will have the right to commercialise the product globally.Unlike traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical conditions.In India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck cancers.Keytruda helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli said.Keytruda has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
5 minutes ago
- Business Standard
Impose Trump's illogical tariff on China, US importers too: Amitabh Kant
Former NITI Aayog CEO and G20 Sherpa Amitabh Kant on Thursday termed the additional 25 per cent tariff imposed by US President Donald Trump on Indian goods as "totally arbitrary" and lacking "any logic," urging that India should consider imposing similar duties on other countries, including US, which still imports critical minerals from Russia. "India should never bend. We should look at a long-term perspective. The Prime Minister has invested a lot in this relationship with the United States over the last decade. We should adopt a long-term perspective and ultimately win the game against the United States," Kant told ANI. He pointed out that other major economies, such as Turkey, the EU, and China, also import significant quantities of energy and minerals from Russia or China. "A 25 per cent tariff is arbitrary. It is not comprehensible to me because then you should also be imposing a 25 per cent tariff on China and Turkey. But you should also be imposing it on Europe, which is a very major importer of gas from Russia, and you should also be imposing it on many of the importers in the United States, as the United States is importing a lot of critical minerals from Russia; all critical minerals are still being imported from China. So it doesn't stand to any logic," he said. Kant also urged India to maintain its strategic autonomy and energy security in the face of proposed US tariffs, saying that India should prioritise its national interests and not compromise on its energy security, especially considering that India's oil imports from Russia are significantly lower than those of China or Turkey. The US has imposed a 50% tariff on Indian goods, citing India's continued purchase of Russian oil. "I'm a believer that India should not compromise on its energy security or its strategic autonomy. We are here for a long-term game, and we must win the long-term war. My belief is that we built up a relationship with the United States over two and a half decades, which was bipartisan. And this attempt to put a 50 per cent duty does not stand to logic because we import oil," he said. Earlier, Trump signed an executive order imposing an additional 25 per cent tariff on imports from India, citing matters of national security and foreign policy concerns, as well as other relevant trade laws. He claimed that India's imports of Russian oil, directly or indirectly, pose an "unusual and extraordinary threat" to the United States. The Ministry of External Affairs (MEA) had termed the US move "unfair, unjustified and unreasonable," and said New Delhi will take "all actions necessary to protect its national interests. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
5 minutes ago
- Time of India
Corporate earnings slow to multi-quarter lows in Q1 as banking, consumer durables weigh
Investors are eyeing a monsoon-led demand revival in the second half, undergirded by government expenditure, to recover from the June-quarter performance. Indian companies experienced a slowdown in revenue and profit growth during the June quarter, hitting multi-year lows due to weak performance in banking, consumer durables, and capital goods sectors. While some sectors like cement and hospitality showed double-digit profit growth, overall operating margins contracted. Tired of too many ads? Remove Ads Sectoral Opportunities Tired of too many ads? Remove Ads Sliding Rates & Bank Margins Aggregate revenue and profit expansions touched multi-year lows in the June quarter on a muted performance across sectors such as banking, consumer durables and capital a sample of 3,197 companies analysed by ETIG, revenue climbed at a seven-quarter low of 6.4%, while net profit expansion of 7.7% was the weakest in at least nine quarters. The poor showing was, in part, offset by double-digit profit growth in cement, chemicals, construction, hospitality, and alcoholic are eyeing a monsoon-led demand revival in the second half, undergirded by government expenditure, to recover from the June-quarter related to US tariffs and geopolitics would also dictate the course - and extent - of any backloaded recovery in FY26. According to Vinit Bolinjkar, research head, Ventura Securities, price inflation and higher operating expenditure impacted profitability."This aligns with the broader market expectations as companies continue to face global macroeconomic challenges, including inflation, geopolitical tensions, and cautious consumer sentiment," said studied sample's operating margin contracted 60 basis points year-on-year to 18.4% in the June quarter, largely influenced by the weakness in the net interest margin of basis point is a hundredth of a percentage point."In the banking sector, margins are likely to remain under pressure in the near term as the impact of rate cuts continues to trickle down," said Vinod Nair, research head, Geojit Nair expects a potential easing in credit costs to help stabilise margins in the second half of the fiscal banks and finance companies, the operating margin of the companies in the sample, at 15.6%, was flat year-on-year. In addition, net profit growth for the truncated sample improved to 10%, and revenue growth was a tad lower at 5.7% compared with the metrics for the full the trend was mixed. Chethan Shenoy, research head, Anand Rathi Wealth , pointed out that industries such as non-banking financial companies (NBFC), infrastructure, and retail reported double-digit, year-on-year sales the other hand, metals and public sector banks showed a slump in sales while the IT sector's performance remained subdued amid circumspect global tech the remainder of FY26, Shenoy believes that opportunities lie in the infrastructure and capital expenditure cycle, a potential consumption recovery in retail and FMCG, and sustained margin tailwinds from lower commodity and logistics costs."However, risks remain from global growth slowdown, commodity price volatility, interest rate trends, and policy changes that could affect sensitive sectors such as energy and PSUs," Shenoy added.
Economic Times
5 minutes ago
- Economic Times
As IPO frenzy cools, companies slash issue sizes to attract investors
Investor optimism cooled in 2025, leading numerous companies, including NSDL and JSW Cement, to reduce their IPO sizes. This adjustment comes amid a surge of new share sales, creating a competitive market where investors have ample choices. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A moderation in investor optimism in 2025 has forced various companies to scale down the sizes of their Initial Public Offerings (IPO) of January, at least 15 companies, such as NSDL Ather Energy , SK Finance, Bluestone, Schloss Bangalore (Leela Hotels), Swastika Infra, and MobiKwik, among others, have pared their offer values to ensure their issues sail through amid a deluge of share far in 2025, 48 companies have raised ₹64,135 crore through IPOs. In 2024, 90 IPOs raked in ₹1,59,535 crore."The supply of IPOs currently is too much, whether SME or main board, both have a very high supply of companies coming to list," said Priyesh Jain, founder and director at Socradamus Capital Pvt Ltd, a merchant banking firm. " So, investors have a lot of options and the liberty to choose where to invest."JSW Cement cut its offer value from ₹4,000 crore to ₹3,600 crore, Ather Energy from ₹3,100 crore to ₹2,626 crore, SK Finance from ₹2,200 crore to ₹1,600 crore, Bluestone from ₹1,000 crore to ₹820 crore, and Schloss Bangalore (Leela Hotels) from ₹5,000 crore to ₹3,500 crore. NSDL reduced the total number of shares in the offer from 5.73 crore shares to 5.01 cut its issue size three times from an initial ₹1,900 crore in 2021, to ₹700 crore in January this year, to ₹572 pushback on IPO valuations has also prompted companies to trim the offer sizes. "IPO sizes are being cut partly because valuations are not matching initial expectations, and investors are seeking a margin of safety," said Bhavesh Shah, managing director and head of Investment Banking at Equirus Capital. "This is prompting promoters to sell fewer shares than originally planned."Uncertain stock market conditions have crimped companies' ability to price IPOs aggressively, though valuations are still at a premium to long-term averages."Institutional investors are wary of such high valuations, as shares often decline significantly within a year of listing," said Deep Shah, senior manager at Unistone Capital Pvt Ltd, a Mumbai-based merchant banking firm. "With numerous IPOs coming up, new companies struggle to command high valuations without peer comparisons."Sebi rules allow companies to increase or reduce IPO size by up to 20% between the draft prospectus and the final offer document, giving issuers room to adjust to market conditions. Companies decide the proportion of the fresh share issue versus the offer for sale depending on these factors."Many now see IPOs not as an end game or a full monetisation event, but as the first step toward long-term value creation and partnership with new investors," said Shah of Equirus.
